These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31505618)

  • 1. Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation.
    Spinthakis N; Gue Y; Farag M; Srinivasan M; Wellsted D; Arachchillage DRJ; Lip GYH; Gorog DA
    Europace; 2019 Sep; 21(9):1297-1306. PubMed ID: 31505618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation.
    Farag M; Niespialowska-Steuden M; Okafor O; Artman B; Srinivasan M; Khan A; Sullivan K; Wellsted D; Gorog DA
    Platelets; 2016 Nov; 27(7):687-693. PubMed ID: 27094212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin.
    Wetmore JB; Yan H; Herzog CA; Weinhandl E; Reyes JL; Roetker NS
    Am J Kidney Dis; 2021 Aug; 78(2):180-189. PubMed ID: 33421454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antithrombotic drugs on the prothrombotic state in patients with atrial fibrillation: The west Birmingham atrial fibrillation project.
    Voukalis C; Lip GYH; Shantsila E
    Thromb Res; 2021 Apr; 200():149-155. PubMed ID: 33610887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin.
    Farr AM; Jing Y; Johnston S; Trocio J; Singhal S; Bruno A; Graham J
    Hosp Pract (1995); 2015; 43(3):172-9. PubMed ID: 26213178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
    Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
    Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
    JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Hijazi Z; Alexander JH; Li Z; Wojdyla DM; Mehran R; Granger CB; Parkhomenko A; Bahit MC; Windecker S; Aronson R; Berwanger O; Halvorsen S; de Waha-Thiele S; Sinnaeve P; Darius H; Storey RF; Lopes RD
    Circulation; 2021 Mar; 143(12):1215-1223. PubMed ID: 33461308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
    Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
    Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial.
    Melloni C; Dunning A; Granger CB; Thomas L; Khouri MG; Garcia DA; Hylek EM; Hanna M; Wallentin L; Gersh BJ; Douglas PS; Alexander JH; Lopes RD
    Am J Med; 2017 Dec; 130(12):1440-1448.e1. PubMed ID: 28739198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation.
    Lau YC; Xiong Q; Shantsila E; Lip GY; Blann AD
    J Thromb Thrombolysis; 2016 Nov; 42(4):535-44. PubMed ID: 27554264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect.
    Guimarães PO; Lopes RD; Wojdyla DM; Abdul-Rahim AH; Connolly SJ; Flaker GC; Wang J; Hanna M; Granger CB; Wallentin L; Lees KR; Alexander JH; McMurray JJV
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):295-301. PubMed ID: 28516318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.